Edward Norbert Van Den Brink

This inventor holds 57 USPTO granted patents and 28 published patent applications and 25 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Genmab A+s, H. Lundbeck A/s, Crucell Holland B.v.. Active years: 2010-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Edward Norbert Van Den Brink. Retrieved from https://idiyas.com/inventor/edward-norbert-van-den-brink

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 57 (Patent Applications = 28)

% Patents Active = 96.5

EPO Patents = 25 (Patent Applications = 12)

Average Co-Inventor Count = 7.1

ph-index = 12

Forward Citations = 481(Granted Patents)

Forward Citations (Not Self Cited) = 379(Dec 10, 2025)

Location History:

Utrecht, DK (2020)
Utrecht, NL (2018 - 2023)
Halfweg, NL (2010 - 2024)

Company Filing History:

Janssen Vaccines & Prevention B.v.

patents

where one patent can have more than one assignee

Years Active: 2010-2026

Loading Chart...

Areas of Expertise:

Monoclonal Antibodies

Bispecific Antibodies

CD3 Antibodies

PD-L1 Binding

c-Met Antibodies

HER2 Antibodies

Synucleinopathy Treatment

Chimeric Antibodies

AXL Binding Agents

Anti-sortilin Antibodies

Binding Agents

57 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12747294 - ANTI-SORTILIN ANTIBODIES AND USE THEREOF (2026-09-29),

2. 12589150 - ANTIBODIES BINDING AXL (2026-03-31),

3. 12570751 - BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF (2026-03-10),

4. 12448459 - Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof (2025-10-21),

5. 12331123 - Agent, uses and methods for treatment (2025-06-17),

6. 11970544 - Antibodies (2024-04-30),

7. 11613575 - Humanized or chimeric CD3 antibodies (2023-03-28),

8. 11548950 - Agent, uses and methods for treatment (2023-01-10),

9. 11542323 - Agents, uses and methods for the treatment of synucleinopathy (2023-01-03),

10. 11524995 - Agents, uses and methods for the treatment of synucleinopathy (2022-12-13),

11. 11512140 - Monoclonal antibodies against c-Met (2022-11-29),

12. 11512137 - Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof (2022-11-29),

13. 11485796 - Inert format (2022-11-01),

14. 11459395 - Binding agents binding to PD-L1 and CD137 and use thereof (2022-10-04),

15. 11421024 - Agents, uses and methods for the treatment of synucleinopathy (2022-08-23),

Title: The Innovative Journey of Edward Norbert Van Den Brink

Introduction: Edward Norbert Van Den Brink is a pioneering inventor hailing from Halfweg, Netherlands. His passion for innovation and problem-solving has led to remarkable contributions in the field of patents and inventions.

Latest Patents: Edward Norbert Van Den Brink holds several cutting-edge patents in various industries, showcasing his versatility and creativity in inventing novel solutions to complex challenges.

Career Highlights: Throughout his illustrious career, Edward Norbert Van Den Brink has consistently pushed the boundaries of innovation. His inventions have not only revolutionized existing technologies but have also paved the way for new advancements in the industry.

Collaborations: Edward Norbert Van Den Brink has collaborated with leading companies, research institutions, and universities to bring his inventions to life. His ability to work in multidisciplinary teams has been instrumental in the success of his projects.

Conclusion: Edward Norbert Van Den Brink's dedication to innovation and his relentless pursuit of excellence have established him as a prominent figure in the world of inventors. His contributions continue to inspire future generations to think outside the box and create solutions that shape the world we live in.

Profile summary based on public USPTO records.